[go: up one dir, main page]

AR027038A1 - Metodo y composicion para el tratamiento del dolor - Google Patents

Metodo y composicion para el tratamiento del dolor

Info

Publication number
AR027038A1
AR027038A1 ARP000106798A ARP000106798A AR027038A1 AR 027038 A1 AR027038 A1 AR 027038A1 AR P000106798 A ARP000106798 A AR P000106798A AR P000106798 A ARP000106798 A AR P000106798A AR 027038 A1 AR027038 A1 AR 027038A1
Authority
AR
Argentina
Prior art keywords
composition
pain
pain treatment
mitigate
compound according
Prior art date
Application number
ARP000106798A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR027038A1 publication Critical patent/AR027038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para el tratamiento del dolor que comprende la administracion de una cantidad efectiva para mitigar el dolor de cualquier compuestode acuerdo con el diagrama estructural (1) en el cual A, D y R1 son como se los definiera en la m emoria. También se describen composiciones farmacéuticas quecomprenden una cantidad efectiva para mitigar el dolor de uncompuesto de acuerdo con el diagrama estructural (1).
ARP000106798A 1999-12-23 2000-12-20 Metodo y composicion para el tratamiento del dolor AR027038A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17190699P 1999-12-23 1999-12-23
US23683500P 2000-09-29 2000-09-29

Publications (1)

Publication Number Publication Date
AR027038A1 true AR027038A1 (es) 2003-03-12

Family

ID=26867559

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106798A AR027038A1 (es) 1999-12-23 2000-12-20 Metodo y composicion para el tratamiento del dolor

Country Status (23)

Country Link
US (1) US20030162783A1 (es)
EP (1) EP1248621A1 (es)
JP (1) JP2003518499A (es)
KR (1) KR20020062983A (es)
CN (1) CN1434714A (es)
AR (1) AR027038A1 (es)
AU (1) AU783499B2 (es)
BG (1) BG106832A (es)
BR (1) BR0016646A (es)
CA (1) CA2394561A1 (es)
CO (1) CO5271687A1 (es)
EE (1) EE200200348A (es)
HK (1) HK1048767A1 (es)
HU (1) HUP0300043A3 (es)
IL (1) IL150202A0 (es)
IS (1) IS6428A (es)
MX (1) MXPA02006154A (es)
NO (1) NO20022990L (es)
NZ (1) NZ519389A (es)
PL (1) PL355850A1 (es)
RU (1) RU2238094C2 (es)
SK (1) SK8802002A3 (es)
WO (1) WO2001047523A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292498A1 (en) * 2000-09-29 2002-04-08 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain
WO2002026741A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
EP1325005A1 (en) * 2000-09-29 2003-07-09 AstraZeneca AB 1,2,5,10-tetrahydropyridazino 4,5-b]quinoline-1,10-diones and their use for the treatment of pain
SE0403172D0 (sv) * 2004-12-23 2004-12-23 Astrazeneca Ab Manufacturing process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1244661A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Compounds and methods for the treatment of pain
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
US6730675B2 (en) * 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain

Also Published As

Publication number Publication date
HUP0300043A2 (en) 2003-05-28
RU2238094C2 (ru) 2004-10-20
KR20020062983A (ko) 2002-07-31
EP1248621A1 (en) 2002-10-16
CO5271687A1 (es) 2003-04-30
AU783499B2 (en) 2005-11-03
SK8802002A3 (en) 2003-06-03
HK1048767A1 (zh) 2003-04-17
CN1434714A (zh) 2003-08-06
PL355850A1 (en) 2004-05-31
EE200200348A (et) 2003-08-15
JP2003518499A (ja) 2003-06-10
IS6428A (is) 2002-06-19
BR0016646A (pt) 2002-10-08
NO20022990D0 (no) 2002-06-20
CA2394561A1 (en) 2001-07-05
BG106832A (bg) 2003-03-31
WO2001047523A1 (en) 2001-07-05
MXPA02006154A (es) 2002-12-05
NO20022990L (no) 2002-08-20
NZ519389A (en) 2004-05-28
HUP0300043A3 (en) 2007-05-02
IL150202A0 (en) 2002-12-01
AU2566001A (en) 2001-07-09
US20030162783A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
SE9504661D0 (sv) New compounds
CR11037A (es) Derivados de 4-tetrazolil -4fenilpiperidina para tratar el dolor (divisional)
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
RU95106649A (ru) Производные бензимидазола в качестве непептидильных антагонистов рецепторов тахикинина, способ получения, фармацевтическая композиция
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
EA200200480A1 (ru) Пероральные композиции противоопухолевых соединений
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
CO4920220A1 (es) Composiciones que contienen compuestos fluoroeter y metodos para inhibir su degradacion en presencia de un acido de lewis
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
UY28536A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
ES2056699T3 (es) Diaminoftalimidas substituidas y analogos.
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
IL146284A0 (en) Androgen glycosides and pharmaceutical compositions containing the same
ES2108130T3 (es) Formulaciones farmacologicas mejoradas.
CO5160318A1 (es) Composicion precursora para preparar un dialitico
AR004474A1 (es) Compuestos de 10-aminoalifatil-dibenz [b,f]oxepinas antineurodegenerativamente activas, utiles para el tratamiento de estados neurodegenerativos y composiciones farmaceuticas que los contienen
ES2062664T3 (es) Poli(acido alfa-hidroxilacrilico) y derivados como compuestos activos antisarro en composiciones orales.
AR027038A1 (es) Metodo y composicion para el tratamiento del dolor
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal